Community-acquired pneumonia remains a major health challenge, affecting more than 500 million individuals globally. Pneumonia can trigger severe pulmonary and systemic inflammation, leading to compromised gas exchange, sepsis, organ failure, and an elevated risk of mortality. Even in high-income countries, the rate of mortality due to this condition is as high as 10–12%. Can glucocorticoids, with their anti-inflammatory and immunomodulatory effects, help decrease mortality among patients with severe community-acquired pneumonia? To know the answer to this question and more, join our esteemed expert Dr.
Pradeep Rangappa , as he discusses the findings of the “CAPE COD trial” in our exciting webinar on 2 nd January 2025, 6:00 PM IST onwards . Stay tuned! Suggested for you Ace This Quiz on Pneumonia! A Rare Case of Aspiration Pneumonia in a 16-year-old Girl ##Disclaimer## The content…
